Compare Aon PLC (AON) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Aon PLC vs State Street SPDR S&P Biotech ETF — how do they compare? Aon PLC trades at $353.5 (market cap $74.74B), while State Street SPDR S&P Biotech ETF trades at $159.12. The key difference: Aon PLC pays a 0.93% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Aon PLC nearer its low. Which is the better fit depends on your goals.
| AON | XBI | |
|---|---|---|
Market Cap | $74.74B | — |
Sector | Financials | Broad Market / Factor |
52-Week High | $381.26 | $164.28 |
52-Week Low | $308.22 | $88.79 |
Enterprise Value | $89.35B | — |
Dividend Yield | 0.93% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AON trades at $351.88, down 1.43% over the past day, with a neutral technical signal and support near $350. The company reported Q2 2026 EPS of $3.81, beating estimates, and has shown consistent revenue growth, reaching $17.18B in 2025. Profitability remains strong with a net income margin of 22.27% and ROE of 44.88%, though valuation ratios like P/E of 19.65 and P/S of 4.37 are elevated relative to historical averages.
The outlook is supported by analyst consensus with a $410 price target and 47% buy ratings, but risks include high debt levels and modest organic growth. Recent news highlights institutional buying and strategic appointments, yet some analysts caution on valuation. Earnings momentum and margin expansion provide upside potential if execution continues.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Aon PLC
Aon is a leading global provider of insurance and reinsurance brokerage and human resource solutions. Its operations are tilted toward its brokerage operations. Headquartered in London, Aon has about 50,000 employees and operations in 120 countries around the world.
Read more on AON →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
